What is the recommended management for a woman over 40 years old with atypical glandular cells of undetermined significance on a Pap smear?

Management of Atypical Glandular Cells in Women Over 40

For a woman over 40 years old with atypical glandular cells (AGC) on Pap smear, you must perform colposcopy with endocervical sampling AND endometrial sampling as part of the initial workup. 1

Initial Workup Algorithm

The age threshold of 35 years (and certainly 40 years) mandates a more comprehensive evaluation due to significantly elevated risk of endometrial pathology:

Required Procedures (All Three):

1. Colposcopy with directed biopsies of any visible lesions
2. Endocervical sampling (endocervical curettage)
3. Endometrial sampling (endometrial biopsy)

This triple approach is critical because women ≥35 years have substantially higher rates of endometrial adenocarcinoma compared to younger women 1. Research confirms that among patients with endometrial pathology detected after AGC diagnosis, 86% were ≥40 years old 2, and postmenopausal women with AGC have a 53% rate of glandular lesions (predominantly endometrial adenocarcinoma) 3.

HPV Testing

• Obtain HPV DNA testing at the time of colposcopy if not already done 1
• Critical caveat: HPV testing alone or repeat cytology alone is unacceptable for initial triage of AGC 1

Risk Stratification by Findings

If Initial Workup Shows No Neoplasia:

For HPV-positive patients:

• Repeat cytology + HPV co-testing at 6 months 1
• Return to colposcopy if HPV remains positive or cytology shows ASC-US or greater
• Return to routine screening only after both tests are negative

For HPV-negative patients:

• Repeat cytology + HPV co-testing at 12 months 1
• Same return-to-colposcopy criteria as above

For unknown HPV status:

• Repeat cytology every 6 months
• Require 4 consecutive negative results before returning to routine screening 1

If CIN (Without Glandular Neoplasia) is Found:

• Manage according to standard CIN guidelines 1

If AGC Subcategory is "Favor Neoplasia" or AIS:

• Proceed directly to diagnostic excisional procedure (cold knife conization or LEEP providing intact specimen with interpretable margins) 1
• Perform concomitant endocervical sampling 1

Clinical Context and Pitfalls

Age-related risk patterns:

• Women >40 years have lower odds of high-grade cervical dysplasia but 12.88 times higher odds of uterine cancer compared to younger women 4
• Overall, 32-33% of women with AGC will have clinically significant lesions 5, 6
• Among significant lesions in women >40, expect roughly equal distribution between glandular lesions (endometrial/endocervical adenocarcinoma, AIS) and squamous lesions (CIN 2/3, invasive squamous carcinoma) 5, 3

Common pitfall to avoid: Do not rely on cytologic subcategories like "favor reactive" versus "favor neoplastic" to determine workup intensity—these are not predictive of significant histology 6. The comprehensive triple evaluation is required regardless of AGC subcategory (except when "favor neoplasia" or AIS is specified, which mandates immediate excision).

Symptoms matter: Abnormal vaginal bleeding is the most common presenting symptom (30.6% of cases) and increases suspicion for significant pathology 5. However, asymptomatic status does not eliminate the need for full evaluation in women ≥40 years.

The evidence strongly supports aggressive initial evaluation in this age group, as the substantial risk of missing endometrial or cervical malignancy (11-15% cancer rate in various studies) 5, 4, 3 far outweighs the burden of comprehensive testing.